Zentalis Pharmaceuticals Announces Follow‑On Stock Offering

What Happened
Zentalis Pharmaceuticals, Inc. announced on August 13, 2026 that it entered into an underwriting agreement to sell 23,000,000 shares of its common stock at $3.50 per share (subject to underwriting discounts and commissions). The underwriters — led by TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. — have a 30‑day option to purchase up to an additional 3,450,000 shares. The company expects the offering to close on August 17, 2026, subject to customary closing conditions. Latham & Watkins LLP issued a legal opinion on the validity of the shares.

Key Details

• Offering size: 23,000,000 shares at $3.50 per share (gross proceeds ≈ $80.5M before fees/expenses).
• Underwriter option: 30 days to purchase up to 3,450,000 additional shares (would add ≈ $12.1M gross if exercised).
• Estimated net proceeds: approximately $75.1 million after underwriting discounts, commissions and estimated offering expenses.
• Use of proceeds: fund clinical trials, preclinical studies, regulatory filings, manufacturing and a companion diagnostic, plus pre‑commercial activities, capital expenditures, working capital and other general corporate purposes.

Why It Matters
This financing is intended to provide near‑term cash to advance Zentalis’s drug development and related activities. For investors, the offering will dilute existing shareholders to the extent shares are issued (and more if the underwriter option is exercised), while increasing the company’s cash runway to support clinical and regulatory programs. The closing is subject to customary conditions, so the transaction is not final until completion.